| My Account | Subscribe | Contact Us | Help |
Home
Diabetes Health
Diabetes Health Professional
- The Starfish Story, Diabetes, and the Poorest Nation in the World
Even drops in the bucket make a difference
- Flying on Insulin
It has been 22 years since Air Canada pilot Steve Steele was grounded with type 1
- Following Dr. Bernstein on Holiday
A traveling couple tries to stick to low carbs
- Sleep Apnea and Diabetes
Here’s something to make you sit up and take notice (maybe 100 times a night): 23 percent of type 2s have obstructive sleep apnea.
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Related Medications Threads on Diabetes Health Forums
Januvia
Updated 47 weeks ago
Januvia, also known as sitagliptin phosphate, is a DPP-IV inhibitor. It prevents, or inhibits, DPP-IV from inactivating GLP-1. GLP-1 is a naturally produced hormone that increases insulin secretion in response to food.
1 comment - Nov 20, 2007 -
New Type 2 Drugs Januvia and Byetta Offer Big Benefits
The 21st century may be remembered as the time when diabetes became a worldwide epidemic. However, it may also be known as the time when the disease was cured.
6 comments - May 2, 2007 -
JANUVIAâ„¢ Approved in the European Union for the Treatment of Type 2 Diabetes
Whitehouse Station, N.J., March 26, 2007 – JANUVIA™ (sitagliptin1), Merck & Co., Inc.'s once-a-day oral treatment for patients with type 2 diabetes, has been granted a license from the European Commission. JANUVIA now becomes the first and only medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood sugar when it is elevated, to be adopted by the European Commission.
0 comments - Apr 18, 2007 -
By October of this year, Merck & Co., Inc., expects the FDA to rule on its novel type 2 drug Januvia (sitagliptin phosphate). On February 15, 2006, the FDA accepted Merck’s New Drug Application (NDA) for Januvia for standard review.
0 comments - May 1, 2006 -
Not Yet Rated